eprintid: 10205615
rev_number: 7
eprint_status: archive
userid: 699
dir: disk0/10/20/56/15
datestamp: 2025-03-05 08:28:19
lastmod: 2025-03-05 08:28:19
status_changed: 2025-03-05 08:28:19
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Leone, Gianmarco
creators_name: Orlando, Francesco
creators_name: Dutey-Magni, Peter
creators_name: Vainauskas, Osvaldas
creators_name: Grist, Emily
creators_name: Ciani, Yari
creators_name: Lall, Sharanpreet
creators_name: Thakali, Suparna
creators_name: Wingate, Anna
creators_name: Wetterskog, Daniel
creators_name: Sachdeva, Ashwin
creators_name: Sydes, Matthew R
creators_name: McPhail, Neil
creators_name: Sreenivasan, Thiagarajan
creators_name: O'Sullivan, Joe M
creators_name: Clarke, Noel W
creators_name: Parmar, Mahesh KB
creators_name: Brown, Louise C
creators_name: James, Nicholas D
creators_name: Demichelis, Francesca
creators_name: Attard, Gerhardt
creators_name: the STAMPEDE collaborators, 
title: Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer:
the STAMPEDE Phase 3 Randomized Clinical Trial
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C10
divisions: D19
divisions: D65
divisions: G99
divisions: J38
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: We previously reported that abiraterone acetate and prednisolone (hereafter abiraterone) added at initiation of androgen deprivation therapy (ADT) improved survival of metastatic and very high-risk locally advanced prostate cancer and that combining with enzalutamide did not change efficacy.1 Using next-generation sequencing on plasma DNA, we previously showed that genomic alterations of the androgen receptor (AR) gene contribute to resistance to abiraterone or enzalutamide when initiated for metastatic castration-resistant prostate cancer after progression with ADT alone.2 It is unknown whether hormone intensification at start of ADT alters selection of AR alterations within the gene body and/or enhancer region.3
date: 2025-02-27
date_type: published
publisher: American Medical Association
official_url: https://doi.org/10.1001/jamaoncol.2024.7051
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2365274
doi: 10.1001/jamaoncol.2024.7051
medium: Print-Electronic
pii: 2830632
lyricists_name: Leone, Gianmarco
lyricists_name: Brown, Louise
lyricists_name: Grist, Emily
lyricists_id: GLEON01
lyricists_id: LCBRO59
lyricists_id: EGRIS50
actors_name: Leone, Gianmarco
actors_id: GLEON01
actors_role: owner
full_text_status: public
publication: JAMA Oncology
event_location: United States
issn: 2374-2437
citation:        Leone, Gianmarco;    Orlando, Francesco;    Dutey-Magni, Peter;    Vainauskas, Osvaldas;    Grist, Emily;    Ciani, Yari;    Lall, Sharanpreet;                                                             ... the STAMPEDE collaborators; + view all <#>        Leone, Gianmarco;  Orlando, Francesco;  Dutey-Magni, Peter;  Vainauskas, Osvaldas;  Grist, Emily;  Ciani, Yari;  Lall, Sharanpreet;  Thakali, Suparna;  Wingate, Anna;  Wetterskog, Daniel;  Sachdeva, Ashwin;  Sydes, Matthew R;  McPhail, Neil;  Sreenivasan, Thiagarajan;  O'Sullivan, Joe M;  Clarke, Noel W;  Parmar, Mahesh KB;  Brown, Louise C;  James, Nicholas D;  Demichelis, Francesca;  Attard, Gerhardt;  the STAMPEDE collaborators;   - view fewer <#>    (2025)    Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.                   JAMA Oncology        10.1001/jamaoncol.2024.7051 <https://doi.org/10.1001/jamaoncol.2024.7051>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10205615/1/Jama_pre_edited.pdf